| Name | Title | Contact Details |
|---|
Horizon Orthopedic is a Brook Park, OH-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Polyzen develops and manufactures disposable medical products and devices for medical industry original equipment manufacturers.
At Longmont United Hospital we are committed to providing compassionate health care in a healing environment and to providing leadership to improve the health of the community we serve. We are a full-service, 201-bed, non-profit hospital. Our specialty areas include Women’s Services, Orthopedics, Cardiology, Oncology, Robotic Surgery, Transitional Care and Acute Medical Services. Our 24-hour Emergency Department is a Level III Trauma Center. Longmont United Hospital is a Planetree Patient-Centered Care Designated hospital in Northern Colorado. We have served the people of Longmont, CO for over 59 years.
Kelly Productions Inc is a Bel Air, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.